On ١٤ نوفمبر ٢٠٢٥, DRMA reported earnings of -1.65 USD per share (EPS) for Q3 25, missing the estimate of -1.62 USD, resulting in a -1.74% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -7.49% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 المحللين forecast an EPS of -1.57 USD, with revenue projected to reach -- USD, implying an نقصان of -4.85% EPS, and -- of --% in Revenue from the last quarter.